We are live on ! Find out more
SLG

Stanley-Laman Group Portfolio holdings

AUM $814M
1-Year Est. Return 40.24%
This Fund
S&P 500
This Quarter Est. Return
+3.23%
1 Year Est. Return
+40.24%
3 Year Est. Return
+82.87%
5 Year Est. Return
+77.64%
10 Year Est. Return
+275.61%
AUM
$463M
AUM Growth
+$88.4M
Cap. Flow
+$76.3M
Cap. Flow %
16.48%
Top 10 Hldgs %
15.82%
Holding
310
New
106
Increased
69
Reduced
87
Closed
41

Top Buys

Rank Stock Value
1
PFPT
Proofpoint, Inc.
PFPT
+$5.74M
2
LJPC
La Jolla Pharmaceutical Company
LJPC
+$5.51M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$5.03M
4
IMPV
Imperva, Inc.
IMPV
+$4.56M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$2.3M

Top Sells

Rank Stock Value
1
TEN
Tenneco Inc. Class A Voting Common Stock
TEN
+$4.9M
2
TSCO icon
Tractor Supply
TSCO
+$4.44M
3
LPNT
LifePoint Health, Inc.
LPNT
+$3.96M
4
WCC
WESCO International
WCC
+$3.55M
5
IDTI
Integrated Device Technology I
IDTI
+$3.36M

Sector Composition

Rank Sector Weight
1 Healthcare 15.33%
2 Technology 14.58%
3 Industrials 10.71%
4 Consumer Staples 7.92%
5 Materials 7.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACAD icon
1
Acadia Pharmaceuticals
ACAD
$4.38B
$9.07M 1.96%
301,105
+157,229
+109% +$5.03M
QLYS icon
2
Qualys
QLYS
$5.61B
$8.82M 1.9%
148,549
+866
+0.6% +$48.7K
PYPL icon
3
PayPal
PYPL
$49.9B
$7.37M 1.59%
100,071
-2,064
-2% -$149K
CW icon
4
Curtiss-Wright
CW
$26.1B
$7.32M 1.58%
60,101
+625
+1% +$73.7K
PANW icon
5
Palo Alto Networks
PANW
$292B
$7.12M 1.54%
294,924
+3,708
+1% +$90.2K
NBIX icon
6
Neurocrine Biosciences
NBIX
$17.2B
$6.92M 1.49%
89,146
+33,723
+61% +$2.3M
FMC icon
7
FMC
FMC
$1.4B
$6.86M 1.48%
83,584
-1,306
-2% -$105K
TIF
8
DELISTED
Tiffany & Co.
TIF
$6.76M 1.46%
65,000
-5,000
-7% -$477K
TRMB icon
9
Trimble
TRMB
$12.3B
$6.55M 1.41%
161,149
+1,833
+1% +$75.1K
ATVI
10
DELISTED
Activision Blizzard
ATVI
$6.49M 1.4%
102,416
+2,150
+2% +$136K
PFPT
11
DELISTED
Proofpoint, Inc.
PFPT
$6.35M 1.37%
71,461
+63,241
+769% +$5.74M
DAR icon
12
Darling Ingredients
DAR
$10B
$6.06M 1.31%
334,131
+3,542
+1% +$61.2K
KSU
13
DELISTED
Kansas City Southern
KSU
$5.83M 1.26%
55,365
+1,915
+4% +$204K
BMRN icon
14
BioMarin Pharmaceuticals
BMRN
$11.5B
$5.79M 1.25%
64,933
-8,293
-11% -$721K
TMO icon
15
Thermo Fisher Scientific
TMO
$198B
$5.72M 1.24%
30,131
+861
+3% +$165K
INGR icon
16
Ingredion
INGR
$6.47B
$5.63M 1.22%
40,277
-1,010
-2% -$133K
CSL icon
17
Carlisle Companies
CSL
$14B
$5.6M 1.21%
49,306
+996
+2% +$109K
ST icon
18
Sensata Technologies
ST
$6.55B
$5.53M 1.19%
108,136
+2,890
+3% +$142K
GRA
19
DELISTED
W.R. Grace & Co.
GRA
$5.51M 1.19%
78,592
+680
+0.9% +$49.3K
LJPC
20
DELISTED
La Jolla Pharmaceutical Company
LJPC
$5.43M 1.17%
+168,653
New +$5.51M
HOLX
21
DELISTED
Hologic
HOLX
$5.38M 1.16%
125,732
+5,639
+5% +$225K
AVNT icon
22
Avient
AVNT
$3.39B
$5.33M 1.15%
122,567
+5,738
+5% +$252K
LH icon
23
Labcorp
LH
$23.2B
$5.25M 1.13%
38,321
+1,827
+5% +$241K
SEE
24
DELISTED
Sealed Air
SEE
$5.16M 1.11%
104,690
+3,882
+4% +$178K
IMPV
25
DELISTED
Imperva, Inc.
IMPV
$4.96M 1.07%
125,011
+109,461
+704% +$4.56M
1
2 3 4 5

Similar funds

VFG
Victory Financial Group Austin, Texas $814M AUM 18.17% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $816M AUM 34.73% 1-Year Est. Return
TFM
TFC Financial Management Boston, Massachusetts $812M AUM 17.34% 1-Year Est. Return
UAG
United Advisor Group Cincinnati, Ohio $811M AUM 18.32% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
BC
Brio Consultants San Francisco, California $818M AUM 13.48% 1-Year Est. Return

Stanley-Laman Group's Q4 2017 Portfolio in Review

As of Q4 2017, Stanley-Laman Group held 310 positions worth $463M, up 24% from $375M the previous quarter. Its ten largest holdings account for 16% of the portfolio.

Stanley-Laman Group deployed $76.3M of net new capital in Q4 2017, opening 106 new positions and adding to 69 existing holdings. Its largest new stake was La Jolla Pharmaceutical Company: 168,653 shares worth $5.43M.

By sector, the portfolio is most concentrated in Healthcare at 15% of assets, down from 18% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was JBT Marel, an estimated $889K trimmed.

  • Stanley-Laman Group's largest Q4 2017 buy was La Jolla Pharmaceutical Company: 168,653 shares worth $5.43M.
  • Stanley-Laman Group added most to Proofpoint, Inc. in Q4 2017, an estimated $5.74M increase.
  • Stanley-Laman Group's biggest Q4 2017 reduction was JBT Marel, cutting an estimated $889K.
  • Stanley-Laman Group fully exited Tenneco Inc. Class A Voting Common Stock in Q4 2017, selling an estimated $4.9M.
  • Stanley-Laman Group's ten largest holdings make up 16% of its $463M portfolio in Q4 2017.
  • Stanley-Laman Group opened 106 new positions and closed 41 in Q4 2017.
  • Stanley-Laman Group's portfolio value rose 24% quarter-over-quarter to $463M.

Based on Stanley-Laman Group's 13F filing for Q4 2017, filed 9 Feb 2018.